| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Extending yesterday's gain, NRx Pharmaceuticals Inc (NASDAQ:NRXP) stock is up more than 26% during the premarket trading on Friday.
NRx's stock opened Thursday up nearly 14% at $11.51 per share after closing Wednesday at $10.11 per share. The stock closed up 62.7% at $16.45 Thursday. Since Monday, the stock has gained almost 95%.
What happened during the week: Yesterday (Thursday), NRx announced it validated the first commercial formulation, with one year or greater stability, of its experimental COVID-19 treatment. NRx also said that it has "achieved a 30-to-50 fold increase" in the manufactured lot size of the drug.
It is developing Relief Therapeutics Holding AG's (OTC: RLFTF) Zyesami (RLF-100, aviptadil) as an intravenous treatment for respiratory failure in critically ill COVID-19 patients.
Earlier formulations of Zyesami were only stable for a few weeks.
Monday, the Company reported that Zyesami prevented the sharp rise in cytokines and was additionally associated with a significant decrease in 60-day mortality.
The next goal for NRx will be to win an emergency use authorization for Zyesami. The Company applied to the FDA for a EUA in June.
Price Action: NRXP shares are up 26% at $20.72 during the premarket session on the last check Friday.
Related content: Benzinga's Full FDA Calendar.
